Novartis eyes Alzheimer's and Parkinson's as it looks to expand the AOC platform acquired in its $12 billion Avidity Biosciences buyout.
Vas Narasimhan, Novartis CEO (Chris J. Ratcliffe/Bloomberg via Getty Images)
May 22, 2026 09:00 AM EDT
R&DPharma
Novartis says Avidity's science could apply beyond muscular dystrophies
Ayisha Sharma
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share,…
The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its…
Novartis says acquisition US biotech company Avidity Biosciences will boost mid-term growth.
Vas Narasimhan, CEO of pharmaceuticals company, Novartis, discusses the company's latest $12 billion acquisition of Avidity…
L’operazione, che riguarda una società specializzata nelle malattie rare, è la più grande acquisizione realizzata sotto la guida…
Novartis raggiunto un accordo per l'acquisizione della statunitense Avidity Biosciences, specializzata nelle terapie Rna per…
